Profile 01
Biotech Gambler
STARTING
$10,000 debt
$8,500 cash
Trust 55
"The pipeline is everything. The cash is temporary."
ADVANTAGE
Phase III pipeline · $380K potential
BLIND SPOT
Cash crisis by Q7. Every move is existential.
STARTING
$8,000 debt
$12,000 cash
Trust 75
"I know how they think. I was them."
ADVANTAGE
NPRA relationships · Transparency instinctive
BLIND SPOT
Investors suspicious of regulatory background.
Profile 03
Research Scientist CEO
STARTING
$7,000 debt
$10,000 cash
Trust 65
"The molecule is right. The market will follow."
ADVANTAGE
R&D advantage · Patent-first strategy
BLIND SPOT
Commercial instinct low. Board wants returns now.
STARTING
$5,000 debt
$22,000 cash
Trust 50
"I've run this playbook before. Different logo, same game."
ADVANTAGE
Capital and distribution ready from day one.
BLIND SPOT
Board pressure fires early. Every loss is visible.
Profile 05
ASEAN Generics Founder
STARTING
$9,000 debt
$14,000 cash
Trust 62
"I know these markets from the inside."
ADVANTAGE
NPRA/BPOM relationships · ASEAN market insight
BLIND SPOT
Global trust starts low. Premium markets resist you.
No prior pharma knowledge needed · Based on real pharmaceutical industry dynamics